Patents by Inventor Christoph Schwaerzler
Christoph Schwaerzler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9841351Abstract: The invention relates to a chassis dynamometer and to a method for simulating the behavior of the vehicle in a chassis dynamometer, comprising an actuator for transferring a longitudinal force to the vehicle, a rotational movement carried out by a wheel or a drive train of the vehicle being measured, a corresponding longitudinal acceleration being determined from the measured rotational movement and the actuator being controlled in accordance with the determined longitudinal acceleration based on the measurement.Type: GrantFiled: April 15, 2015Date of Patent: December 12, 2017Assignee: Kristl, Seibt & Co. Gesellschaft m.b.H.Inventors: René Reiter, Christoph Schwaerzler, Michael Palzer, Roland Margelik
-
Publication number: 20170038274Abstract: The invention relates to a chassis dynamometer and to a method for simulating the behavior of the vehicle in a chassis dynamometer, comprising an actuator for transferring a longitudinal force to the vehicle, a rotational movement carried out by a wheel or a drive train of the vehicle being measured, a corresponding longitudinal acceleration being determined from the measured rotational movement and the actuator being controlled in accordance with the determined longitudinal acceleration based on the measurement.Type: ApplicationFiled: April 15, 2015Publication date: February 9, 2017Inventors: Rene REITER, Christoph SCHWAERZLER, Michael PALZER, Roland MARGELIK
-
Patent number: 8999708Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: October 3, 2013Date of Patent: April 7, 2015Assignee: Novartis AGInventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
-
Patent number: 8945548Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: October 3, 2013Date of Patent: February 3, 2015Assignee: Novartis AGInventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
-
Publication number: 20140248265Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNy production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNy production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: March 20, 2014Publication date: September 4, 2014Applicant: NOVARTIS AGInventors: Michael Otto BARDROFF, Jose M. CARBALLIDO HERRERA, Daniela DELLA DUCATA, Christoph HEUSSER, Ute JAEGER, Christoph SCHWAERZLER
-
Patent number: 8715657Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: March 29, 2010Date of Patent: May 6, 2014Assignee: Novartis AGInventors: Michael Bardroff, Jose M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Publication number: 20140120101Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicant: NOVARTIS AGInventors: Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
-
Publication number: 20140099708Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: October 3, 2013Publication date: April 10, 2014Applicant: NOVARTIS AGInventors: Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
-
Patent number: 8574573Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: October 4, 2011Date of Patent: November 5, 2013Assignee: Novartis AGInventors: José M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
-
Publication number: 20120082681Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: October 4, 2011Publication date: April 5, 2012Applicant: NOVARTIS AGInventors: José M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
-
Publication number: 20120034231Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: March 29, 2010Publication date: February 9, 2012Applicant: NOVARTIS AGInventors: Michael Bardroff, José M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Publication number: 20100254993Abstract: Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases.Type: ApplicationFiled: April 15, 2010Publication date: October 7, 2010Inventors: JOSÉ M. CARBALLIDO HERRERA, JAN E. DE VRIES, CHRISTOPH SCHWAERZLER
-
Patent number: 7740843Abstract: Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases.Type: GrantFiled: August 2, 2005Date of Patent: June 22, 2010Assignee: Novartis AGInventors: José M. Carballido Herrera, Jan E. De Vries, Christoph Schwaerzler
-
Publication number: 20080241160Abstract: Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases.Type: ApplicationFiled: August 2, 2005Publication date: October 2, 2008Inventors: José M. Carballido Herrera, Jan E. De Vries, Christoph Schwaerzler